Astera Labs (NASDAQ: ALAB) Stock Price Rises 10% - Is It Worth Buying?

Astera Labs, Inc. (NASDAQ: ALAB) saw a notable increase in its stock price, trading up by 10% during mid-day trading on Tuesday. The stock reached a high of $66.49 before settling at $67.89. A total of 3,293,476 shares changed hands during the session, which is a 13% decline from the company's average volume of 3,794,817 shares. The previous closing price was $61.70.

Wall Street Analysts Outlook

Astera Labs has become a focal point for various analysts recently. On November 18, Citigroup initiated coverage on the company, giving it a "buy" rating along with a target price of $120.00. Furthermore, Northland Capital Markets upgraded Astera Labs from a "hold" to a "strong-buy" on January 28. On the same day, Morgan Stanley adjusted their price target from $142.00 to $114.00, maintaining an "equal weight" rating. Barclays also increased their target from $87.00 to $135.00 and rated the company as "overweight". Additionally, on February 11, Craig Hallum enhanced their price target from $105.00 to $125.00 and reiterated a "buy" rating. Summarizing these evaluations, one analyst has suggested a hold, while eleven others recommend buying, resulting in a consensus rating of "Buy" with an average price target of $115.33.

Astera Labs Stock Performance Overview

The company currently has a market capitalization of $10.59 billion and a price-to-earnings ratio of -37.76. Its 50-day moving average stands at $98.99, while the 200-day moving average is $87.81. Last reported quarterly earnings indicate that Astera Labs earned $0.10 per share, which fell short of analysts' expectations of $0.26 by $0.16. The company has shown a negative return on equity of 10.40% and a negative net margin of 21.05%. Analysts forecast Astera Labs will achieve an earnings per share of 0.34 for the current year.

Insider Trading Activities

In recent insider trading news, General Counsel Philip Mazzara sold 50,000 shares on February 20, valuing the transaction at approximately $4.37 million, at an average price of $87.46 per share. Consequently, Mazzara now holds 191,209 shares of Astera Labs, worth about $16.72 million, marking a 20.73% reduction in his position. Additionally, Director Michael E. Hurlston sold 2,500 shares on February 18, receiving about $230,200 at an average price of $92.08. Following this sale, Hurlston’s remaining shares amount to 91,794, valued at roughly $8.45 million, reflecting a 2.65% decrease in ownership. Over the last 90 days, insiders have sold a total of 570,990 shares worth approximately $50.24 million.

Action from Hedge Funds and Institutional Investors

There has been recent activity involving hedge funds and institutional investors regarding their stakes in Astera Labs. Whittier Trust Co. of Nevada Inc., for instance, purchased a new stake valued at around $25,000 in the fourth quarter. Steward Partners Investment Advisory LLC raised its holdings by 99.0%, now owning 199 shares valued at $26,000 after the acquisition of additional shares. Other firms like Kestra Investment Management LLC and Global Retirement Partners LLC also increased their stakes considerably during the same quarter. Currently, institutional investors own 60.47% of Astera Labs' stock.

About Astera Labs

Astera Labs, Inc. specializes in designing, manufacturing, and selling semiconductor-based connectivity solutions aimed at cloud and AI infrastructure. Their Intelligent Connectivity Platform includes a range of products for data, network, and memory connectivity, built on a comprehensive software-defined architecture that facilitates efficient deployment and operation of high-performance infrastructures.

Final Thoughts

Before investing $1,000 in Astera Labs, it is vital to consider various insights. While the company currently holds a buy rating from analysts, it's recommended to compare it with other stocks that analysts may regard more favorably.

Astera, Stocks, Investors